Item 8.01 Other Events.

On January 19, 2023, Seagen Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses